arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences

FT Global Pharmaceutical and Biotechnology Conference

Embracing Disruption for a New Era in Health

London |  - 
Speakers include:
Mene Pangalos

Mene Pangalos

AstraZeneca

Deborah Harland

Deborah Harland

SR One

Bruno Holthof

Bruno Holthof

NHS Oxford University Hospitals

Overview

The global life sciences industry is facing a level of disruption unprecedented in its long history. Once considered the holy grail of medicine, a new generation of gene-based therapies is dawning at last, holding out the promise of a paradigm shift from treatment to care, but also challenging our healthcare systems’ ability to afford the new age of biology.  China, meanwhile, is rising as a force to be reckoned with, both in terms of its potential for drug development, as well as in its ready embrace of digital technologies to transform R&D, health treatment and services.

The Financial Times Annual FT Global Pharmaceutical and Biotechnology Conference, now in its 36th successful year brings together the industry’s top executives and visionaries to explore the latest trends from biosimilars, to digital therapeutics to next generation neuroscience and diagnostics set to reshape the industry far into the future.

fallback
fallback Add to my Calendar 11/05/2018 13:30:0011/06/2018 18:00:00trueFT Global Pharmaceutical and Biotechnology ConferenceThe global life sciences industry is facing a level of disruption unprecedented in its long history. Once considered the holy grail of medicine, a new generation of gene-based therapies is dawning at last, holding out the promise of a paradigm shift from treatment to care, but also challenging our healthcare systems’ ability to afford the new age of biology.  China, meanwhile, is rising as a force to be reckoned with, both in terms of its potential for drug development, as well as in its ready embrace of digital technologies to transform R&D, health treatment and services.The Financial Times Annual FT Global Pharmaceutical and Biotechnology Conference, now in its 36th successful year brings together the industry’s top executives and visionaries to explore the latest trends from biosimilars, to digital therapeutics to next generation neuroscience and diagnostics set to reshape the industry far into the future.FT-Global-Pharmaceutical-and-Biotechnology-Conference0fd3ab4eda1b8c59fc5147f57691a815MM/DD/YYYY

2017 Photos

View photos from the 2017 Summit here.

37698300154_663ef018d4_k

fallback

2017 Testimonials

“The FT Pharma and Biotech Conference is the leading event for getting a glimpse of the future of healthcare.” Philipp Gutzwiller, Global Head of Healthcare, Lloyds Bank

“FT Pharma is an insightful meet for learning and networking” Seppa Orsila, Executive Chairman, Modulight

“The FT conference offers a perfect balance of hard-hitting topics that are relevant to today's pharma/biotech industries” Faraz Kermanz, Comms Manager, EFPIA

“Great meeting to hear about the latest thinking from senior leaders in life sciences industry” Matt Cooper,  Business Development Director, Nihr Clinical Research Network

“FT conferences really provide high value information and world class speakers” Viky Maniala, Managing Director, Transped

fallback

Speakers list (17)

Mene Pangalos

Mene Pangalos

Executive Vice-President, Innovative Medicines and Early Development Biotech Unit
AstraZeneca
Deborah Harland

Deborah Harland

Partner
SR One
Bruno Holthof

Bruno Holthof

CEO
NHS Oxford University Hospitals
Chris Edson

Chris Edson

CEO
Our Path
Richard Francis

Richard Francis

CEO
Sandoz
Christian Hogg.

Christian Hogg.

CEO
Chi-Med

Mr Hogg joined Chi-Med in 2000, as its first employee, and has since led all aspects of the creation, implementation and management of the company’s strategy, business and listings.  This includes the establishment of the company’s Innovation Platform, which now comprises eight clinical drug candidates, primarily in oncology, in over 30 clinical studies around the world and a scientific team of over 330 people based in Shanghai.   Furthermore, the acquisition and operational integration of assets that led to the formation of the company’s Commercial Platform which manufactures and markets over 200 drugs through a team of over 3,300 marketing personnel covering over 300 cities and towns in China. Prior to joining Chi-Med, Mr Hogg spent ten years with P&G starting in the US in Finance and then Brand Management in the Laundry and Cleaning Products Division. Mr Hogg then moved to China to manage P&G’s detergent business followed by a move to Brussels to run P&G’s global bleach business. Mr Hogg received a Bachelor’s degree in Civil Engineering from the University of Edinburgh and an MBA from the University of Tennessee.

Keiron  Sparrowhawk

Keiron Sparrowhawk

Founder and CSO
MyCognition
Professor Sir John Bell

Professor Sir John Bell

Regius Professor of Medicine, Government Advisor on UK Life Sciences Strategy
Oxford University

Professor Sir John Bell is Regius Professor of Medicine at Oxford University and the former President of the Academy of Medical Science. He has been extensively involved in the development of research programmes in genetics and genomics and in the development of clinical research programmes across the UK. Professor Bell was the Founder of the Wellcome Trust Centre for Human Genetics and has led the significant expansion in biomedical research activities in the Clinical School in Oxford since 1992. He is a non-executive director of Roche AG (since 2001) and of Genentech (since 2009). He is also a member of the Bill and Melinda Gates Foundation Scientific Advisory Committee and a Board Member of the UK Clinical Research Collaboration and UK Biobank. Professor Bell is currently the Life Sciences Champion to the UK Prime Minister advising on Life Sciences Strategy.  

William Mayo

William Mayo

Chief Information Officer
The Broad Institute-MIT and Harvard
Udit Batra

Udit Batra

Member of the Executive Board, CEO Life Science
Merck
Julie Gerberding

Julie Gerberding

Executive Vice President, Communications, Global Policy, and Population Health & Chief Patient Officer
Merck & Co

Dr Julie Gerberding is responsible for Merck’s commercial portfolio of vaccines, planning for the introduction of vaccines from the company's pipeline, and accelerating access to vaccines around the world. She also co-chairs the Board of Sanofi Pasteur MSD vaccines (a joint venture in Europe). Dr Gerberding served as Director, US. Centers for Disease Control and Prevention (2002-2009) where she led numerous emergency responses to public health crises, including anthrax bioterrorism, SARS, Ebola, and natural disasters. Dr Gerberding is a passionate advocate for sustainable global health solutions and serves on the Boards of Directors of Project HOPE, Accordia Global Health Foundation and the MSD Wellcome Trust Hilleman Laboratories (India).

Dr Hans-Georg Eichler

Dr Hans-Georg Eichler

Senior Medical Officer
European Medicines Agency (EMA)

Hans-Georg Eichler, MD, MSc, is the Senior Medical Officer at the European Medicines Agency (EMA) in the United Kingdom, where he is responsible for coordinating activities between the Agency’s scientific committees and giving advice on scientific and public health issues. Prior to joining the European Medicines Agency, Dr Eichler was at the Medical University of Vienna in Austria for 15 years. He was Vice-Rector for Research and International Relations from 2003, and Professor and Chair of the Department of Clinical Pharmacology from 1992. His other previous positions include president of the Vienna School of Clinical Research and co-chair of the Committee on Reimbursement of Drugs of the Austrian Social Security Association. His industry experience includes time spent at Ciba-Geigy Research Labs, UK, and Outcomes Research at Merck & Co, in New Jersey. In 2011, Dr Eichler was the Robert E. Wilhelm fellow at the Massachusetts Institute of Technology’s Center for International Studies, participating in a joint research project under the MIT’s NEWDIGS initiative.

Dr Eichler graduated with an MD from Vienna University Medical School and a Master of Science degree in Toxicology from the University of Surrey in Guildford, UK. He trained in internal medicine and clinical pharmacology at the Vienna University Hospital as well as at Stanford University.

Nick  Leschly

Nick Leschly

Chief Bluebird
Bluebird Bio
Jane  Griffiths.

Jane Griffiths.

Global Head
Actelion
Billy Boyle

Billy Boyle

Founder and CEO
Owlstone Medical
Mike Gladstone

Mike Gladstone

Global President, Internal Medicine, Pfizer Innovative Health
Pfizer
Bertrand Bodson

Bertrand Bodson

Chief Digital Officer
Novartis
fallback

Chaired by (2)

David  Crow

David Crow

Senior US Business Correspondent
Financial Times

David Crow is a Senior US Business Correspondent for the Financial Times, covering telecoms, technology, and pharmaceuticals. He is based in New York. He previously worked on the FT's main news desk in London, where he edited the front page of the print edition. Before joining the FT he was Managing Editor of City AM, the London financial newspaper.

Mr Crow has an MA in English Literature from the University of Glasgow.

Sarah  Neville

Sarah Neville

Global Pharmaceuticals Editor
Financial Times

Sarah Neville began her career on local and regional newspapers, eventually becoming political editor of the Yorkshire Post. In 1995 she was awarded the Laurence Stern Fellowship on the Washington Post. She joined the Financial Times in 2001 and has since held a series of senior roles, including Weekend News Editor, Analysis Editor, UK News Editor and public policy editor in 2011. She was appointed Pharmaceuticals Correspondent in 2016.

Advisory Board (11)

Jessica Federer.

Jessica Federer.

Head of Digital Development
Bayer

Jessica Federer leads digital development at Bayer, a global enterprise advancing Science For A Better Life in the areas of human, animal and plant health. Recognized as one of the top 100 global CDOs and a leading Health Tech Influencer, Federer is passionate about translating digital developments into meaningful public health advancements. Federer previously held positions in Regulatory Affairs, Market Access, Communications and Public Affairs, and worked at the Agency for Healthcare Research and Quality at the US Department of Health and Human Services.

Jessica serves as a Board Member for the MedicAlert Foundation, the UN Agency for Information and Communications Technology (ITU), the World Economic Forum Digital Transformation of Industries Initiative for Chemistry and Advanced Materials, and the Bayer Cares Foundation Committees for both the Employee Volunteer program and the Aspirin Social Innovation Award.

She received a Master of Public Health degree from the Yale School of Public Health, and a Bachelor of Science from The George Washington University. Originally from St. Louis, Missouri, she now lives in Düsseldorf, Germany.

Ulrich  Mühlner

Ulrich Mühlner

Founder and Managing Director
GrowthCube Partners

Ulrich Mühlner is a senior healthcare executive with 17 years of industry experience. In 2016, he started GrowthCube Partners and became an active startup investor and entrepreneur to enable life-changing healthcare innovations by joining forces with scientists, innovators, and entrepreneurs, and - together - translating groundbreaking ideas, discoveries, and inventions into services and products that make a real difference to people’s lives. Dr Mühlner is particularly passionate about radically transforming the pharma industry through Big Data, Artificial Intelligence, and Deep Learning. In addition, Dr Mühlner is the CEO, Chairman and Co-Founder of docdok.health Ltd, a recently founded company with the mission to transform the quality, delivery and experience of medical care for both doctors and patients through its innovative cloud-based connected personalised health communication platform. He also serves as the CEO of E-Medicus Ltd. and globally as board member and advisor to biopharma and digital health/health tech companies, as well as international organisations and  leading academic institutions. Previously, Dr Mühlner worked at Novartis and The Boston Consulting Group (BCG). At Novartis he served as Director and Head Global Corporate Strategy, Global Head Outcomes Technologies Incubator.In this role, he was responsible for the multi-billion dollar portfolio transformation strategy and spearheaded globally the digital health activities across Novartis leading to major digital health partnerships (Google/Verily, IBM, Proteus) with the aim to increase the value of the Novartis portfolio through ‘beyond-the-drug’ real-world outcomes solutions. In total, Dr Mühlner successfully executed deals with a volume of $350mn. Dr Mühlner studied Biochemistry in Hannover and Munich, and earned a PhD degree in Biochemistry and Molecular Biology based on his research on molecular mechanisms of cancer development at the Research Institute of Molecular Pathology (I.M.P.) in Vienna.

Lisa  Anson

Lisa Anson

President
AstraZeneca UK
Julie  Ducharme

Julie Ducharme

Managing Director
Mundipharma Research
Virginia Acha

Virginia Acha

Director, Regulatory Affairs
Amgen

Christina Nesheva

Christina Nesheva

Operations Director, Hive Innovation Unit,
ViiV
Mike Standing

Mike Standing

EMEA Life Sciences and Healthcare Lead
Deloitte

Mike Standing is the Life Sciences and Healthcare industry leader for Deloitte for EMEA. Mr Standing has consulted to leading pharmaceutical and healthcare organisations in Europe, US and China for over 20 years, focusing on commercial strategy, operations and R&D productivity. In addition, he is currently leading major programmes to understand how real world evidence can transform health outcomes and productivity. He also advises governments on building healthcare clusters and is a member of the UK's Global Medical Excellence Cluster (GMEC) Advisory Board. Prior to joining Deloitte, Mr Standing was Co-Head of Life Sciences for the Monitor Group and Global Head of Capgemini's Life Sciences business. He is a graduate of Durham and Cambridge Universities and is based in London.

Richard  Mason

Richard Mason

Head
Johnson & Johnson Innovation EMEA

Richard Mason is the Head of Johnson & Johnson London Innovation Centre and is responsible for Johnson & Johnson Innovation within the EMEA region. In this role, Dr Mason leads a team of transaction and scientific innovation experts to identify and develop a diverse portfolio of early stage partnerships and investments across all three sectors of Johnson & Johnson. Prior to joining Johnson & Johnson Innovation, he was CEO of XO1 Limited until the company was acquired by Janssen in March 2015. Prior to his role at XO1, Dr Mason was Head of Strategy and Business Development at specialist pharmaceutical and medical device company BTG Plc, where he led its transformation into a leading interventional medicine company through multiple acquisitions. Mr Mason also served as an Executive-in-Residence for Advent Venture Partners LLC where he was a turnaround CEO for several portfolio companies. Previously he was Senior Vice President, Business Development at Cambridge Antibody Technology (CAT). Dr Mason trained in medicine at the St Bartholomew’s Hospital Medical College and worked in clinical practice in internal medicine before entering the biotechnology industry. He also has a degree Immunology from UCL and an MBA from The Judge Business School, University of Cambridge, where he is currently a Fellow in Healthcare Management and teaches the MBA elective in biotechnology and pharmaceuticals

Francesco  De Rubertis

Francesco De Rubertis

Founder and CEO
Medicxi

Francesco De Rubertis is Partner and Co-Founder of Medicxi. Prior to this, he was with Index Ventures for 18 years, having joined the firm in 1997 to launch its life sciences practice. While at Index life sciences, he spearheaded the creation and adoption of an asset-centric investment strategy and led the growth of the firm. At Medicxi he also oversees the firm’s operations. Among Dr De Rubertis’s investments are CellZome (acquired by GlaxoSmithKline), Egalet (NASDAQ: EGLT), GenMab (NASDAQ Copenhagen: GEN), GenSight Biologics (Euronext: SIGHT), Micromet (acquired by Amgen), Minerva Neurosciences (NASDAQ: NERV), Molecular Partners (Swiss: MOLN.SW), PanGenetics (acquired by Abbott), Parallele Biosciences (acquired by Affymetrix, NASDAQ: AFFX), Profibrix (acquired by The Medicines Company), and Versartis (NASDAQ: VSAR). Dr De Rubertis received a BA in Genetics and Microbiology from the University of Pavia and a PhD in Molecular Biology from the University of Geneva, and was then a postdoctoral scientist at the Whitehead Institute at MIT. He is a Chartered Financial Analyst and serves on the main board of the University of Geneva. Dr De Rubertis was named by BioWorld as one of 28 “movers and shakers” predicted to shape the biotechnology industry over the next two decades.

Colin Orford

Colin Orford

Senor Vice President, Drug Development Services and Consulting
ICON

Colin Orford is ICON’s Vice President, Product Development, focusing on developing new models of drug development which range in scope from virtual development with small companies through to externalised development for large pharmaceutical companies. Dr Orford has 25 years of experience in the pharmaceutical sector gained at GSK, Novartis, Quintiles and Eisai. Over the course of Dr Orford’s career, he has been responsible for transitioning approximately 13 molecules, targeting MDD, Sleep disorders, Schizophrenia and Alzheimer’s Disease, from Phase 0, through proof of concept and, into late phase development.  Dr Orford holds a P.D in microbial biochemistry and a PhD in endocrinology. 

Tim de Gavre

Tim de Gavre

Country Head UK
Sandoz
fallback

Agenda - 5th Nov

  • 1:30pm
    Opening Remarks from the Chair
  • 1:35pm
    CEO Keynote Address/Interview
  • 1:50pm
    Panel: Big Bang? Industrial Strategy - Creating a Successful Life Sciences Economy

    The UK has recently announced its sector deal for life sciences as part of its Industrial Strategy. Other countries
    around the world are also making efforts to build their life sciences sectors in recognition of the industry’s hoped
    for contribution to economic growth.

    • How effective will the UK’s life sciences strategy be in achieving its stated objectives? What difference will it make? Will it provide a ‘big bang’ for life sciences? Will it enable patients to achieve ‘the best standards of care’ and improve access?
    • Are healthcare systems ready and able to adopt and support the innovation which will emerge from these industrial strategy endeavours? Is the necessary alignment of payment, regulatory and development models in place to ensure success?
    • What does it take to create a truly competitive life science industry? How do you ‘go beyond the network’, for instance, to enable the innovation at the interface between industry academia and healthcare systems that creates new sources of data and the development of new drugs?
    • What is the role of clusters/ ecosystems, and how sustainable are all the new clusters/superclusters as growing numbers of countries competing in this space?
    • How important is life science to the economy, and it is money invested well?

    Jane Griffiths, Global Head, Actelion

    Professor Sir John Bell, Regius Professor of Medicine, Oxford University

    Udit Batra, CEO, Life Sciences, Merck

    Dr Bruno Holthof, CEO, NHS Oxford University Hospitals

  • 2:40pm
    Presentation/Keynote Interview: The Future for Generics and Biosimilars

    Richard Francis, CEO, Sandoz

  • 2:55pm
    Networking Coffee Break
  • 3:10pm
    China - A Disruptive Force in Life Sciences: Leader or Follower?

    China is stepping up its investment in life sciences, and is aiming to take a lead in key emerging areas to include genomics, gene editing and gene therapies. It is also now the second largest pharmaceutical in the world and is facing an epidemic of chronic and age related diseases. Recent moves by the industry regulator are paving the way for faster drug approvals and greater access for patients to advanced therapies. Meanwhile, China is embracing digital at a pace which eclipses the efforts in most other countries, and lacking the burden of legacy primary health care systems, is creating innovate new treatment and service models.

    • How is healthcare reform and the regulatory environment for life sciences in China evolving and what does it mean for pharma?
    • How is digital health evolving in China? What innovative approaches and strategies is China adopting to deal with ageing and management of chronic diseases? What are the implications of China’s approach to data as a public asset?
    • Will China be a leader or follower in drug development? What is the true level of innovation and ambition in China-the vision of China innovation 2020/2025?
    • What R&D strategies are Chinese life sciences company’s adopting, and what are the barriers to Chinese companies becoming fully fledged drug innovators? How might the emergence of Chinese innovation redefine the pathways for discovery and development of new drugs? What new innovations and approaches could we see emerging?
    • Will Chinese life sciences companies steal a lead by virtue of prowess in AI, computing, genomics and more lapse regulations with regard to advanced gene-based medicine?
  • 4:00pm
    Investor Panel

    In this session our panel of leading investors – to include leading fund managers, corporate venture and charity investors - will share their views on the outlook for the industry and challenges ahead. The session will include views on the current round of deal making /M&A and consolidation and the implications for the industry. Will investors provide patient long-term capital to support the industry’s on-going transformation, including digital initiatives without proven IP and a framework for the valuation and monetisation of data, and potentially lower initial margins? Where do investors see opportunities emerging?

    Deborah Harland, Partner, SR One

  • 5:00pm
    Close of Day One

Agenda - 6th Nov

  • 9:00am
    Opening Remarks from the Chair
  • 9:05am
    FT Keynote Address/CEO Interview
  • 9:25am
    Panel: Big Data, Big Deal?

    What will it mean for the industry as payers continue to make advances in their ability to have continuous, real-time data enabling them not only to monitor and compare effectiveness of drugs, but to continuously assess the health of patients? How are payers strategies evolving in this space? In theory, this will lead to better patient care and better clinical trials, but there are many challenges remaining before the ‘data utopia’ becomes a reality, to include the lack of agreement on differening definitions of what constitutes value. How far are we from achieving the data utopia which underpins the many industry efforts to achieve greater productivity and patient focus with the help of technology? Does date have real value, and how do you get that value? Has data become too much, too complex and beyond the ability of life science and regulators to manage it? How much evidence is enough? Or too much? Where do we go from here? Enormous advances in gathering date and evidence, have been made but implementation has been challenging: Is the next stage of the digital health revolution a move to simplicity (e.g. the Uber health application)?

    Bertrand Bodson, Chief Digital Officer, Novartis

    William Mayo, Chief Information Officer, The Broad Institute-MIT and Harvard

  • 10:15am
    Panel: Innovate Like a Start-Up: A New Future for R&D?

    In this session, our panel of leading Heads of R&D will share their views on the challenges facing R&D, and the strategies and approaches to reinvigorate drug development and research. Issues to be addressed could include:

    • New R&D models-prospects and challenges of public-private partnerships. Will we see more collaborations between government and industry to resolve the big research challenges which are beyond the capacity for big pharma to handle alone (e.g Alzheimer’s)?
    • How are R&D departments delivering on their ambition to do research more like entrepreneurial biotechs?
    • Virtual clinical trials-what do we need to do to make this a reality? Can clinical trials become treatment options?
    • The digital prescription for R&D – is big data slowing down drug development?
    • Digital + drugs and Digital therapeutics-what’s the verdict?
    • Is there a case for optimism in R&D?
  • 11:00am
    Networking Coffee Break
  • 11:20am
    Panel: Partnerships and Collaborations: What Works and Doesn't Work?

    The aim of this session is to provide visibility regarding what’s working and not working in the multiple types of partnering and collaborations being undertaken and explored by life sciences companies-from JV, to licensing to consortia and tie-ups increasingly with non-traditional industry players.

    • What’s working and not working? What have been the successes and challenges?
    • What are the trends in collaboration and partnering?
    • What novel types of collaborations might we see emerging?
  • 12:00pm
    Panel: Patient-Centred Care and Patient - Centred Outcomes: Hope or Hype?

    Life science companies are working to place ‘serving the patient’ at the centre of their mission. The capture ofpatient focused data is becoming an essential part of drug approval and the reimbursement process and a focus on patient centricity helps build patient trust, can improve outcomes and adherence and help gain better acceptance by payers, providers, regulators and patients.

    • What are the strategies to support patient centricity on a full life-cycle basis? How is a focus on the patient impacting decision making? What does an all embracing, patient-centric life science company of the future look like? Are patient-centric approaches delivering on ROI?
    • How do you build a patient-centric corporate culture?
    • How are regulation and payer requirements regarding patient centricity and outcomes evolving?
    • Case study of a patient journey in one disease area: what were the experiences and learnings? How do patients define value and how do you measure it?

    Mike Gladstone, Global President,  Internal Medicine, Pfizer Innovative Health, Pfizer  

    Hans-George Eichler, Senior Medical Officer, European Medicines Agency (EMA)

  • 12:40pm
    Lunch
  • 2:00pm
    New Industry Paradigms: Prevention - What is the Role for Pharma in Population Health Management?

    A focus on prevention and its potential for cost savings will become increasingly important if healthcare systems are to be able to afford the highly innovative, high-cost drugs which are coming our way. However, interventions focused on prevention are difficult to test and validate, and the economics are also fundamentally challenging. How can pharma play a role and excel in this space? Can the industry make money from prevention? What does it take to succeed in this space (e.g owning a consumer business)?

    Chris Edson, CEO, Our Path

  • 2:40pm
    Panel: From Treatment to Cure-Gene Therapy and Gene Editing- How will gene-based therapies transform medicine and healthcare?

    Long considered the holy grail of medicine, the era of genetic medicine is dawning at last. The recent FDA approval of a gene therapy marks the advent of a new era of cell and gene- based therapies that try to hack the body’s biology to tackle disease and hold out the promise of a paradigm shift from treatment to cure. Will gene therapies become the mainstay in treating and possibly curing our most devastating and intractable diseases?

    • How can pharma work with effectively with healthcare providers and patients to bring the benefits to patients?
    • Given the high price tag, what will be the impact on healthcare systems and how can they be paid for?
    • What are the viable alternative pricing and financing models to ensure the full potential of these new treatments are realized, and their affordability and access is assured?
    • How do you value and put a price tag on potential cures?
    • What are the viable alternative pricing and financing models to ensure the full potential of these new treatments are realized and their affordability and access is assured?

    Nick Leschly, Chief Bluebird, Bluebird Bio

    Katrine Bosley, CEO, Editas Medicine

  • 3:20pm
    Networking Coffee Break
  • 3:40pm
    Panel: Envisioning the Future of Diagnostics

    Some 70% of medical decisions, it is claimed are driven by diagnostics. As we enter the era of precision medicine, tailored therapeutics and AI, and as ever more rare diseases are investigated, diagnostics will continue to grow and the definition of what constitutes diagnostics will evolve.

    • A vision for the future of diagnostics
    • How will AI transform diagnostics?
    • The role of digital diagnostics-how robust are they? The challenges of regulating medical algorithms
    • Regulation and reimbursement challenges
    • Beyond oncology: prospects for expanding RX/DX/companion diagnostic to chronic disease and other disease states
    • Opportunities and challenges of early stage diagnostics
    • Next Frontiers in diagnostics: Immune system mapping and diagnostics: facial recognition diagnostics
    • The pitfalls of genetic testing-will we overwhelm the health system with the worried well?

    Billy Boyle, Founder and CEO, Owlstone Medical 

  • 4:30pm
    Presentation/ Panel New Horizons in Neuroscience/CNS

    What’s new in Neuroscience/CNS?

  • 4:50pm
    Win Big, Lose Big? An Industry Call to Action

    Beyond R&D, how will tech and data disruption potentially transform other aspects of the business, to include commercial and supply chain? Will digital spell the end of the sales force and marketing as we know it? Will the industry become increasingly commoditised as these disruptions gradually chip away at all aspects of the business? Is the era of complacency regarding the disruptions set to reshape the industry now over? Will completely new business, skills and leadership models be needed? What is the key to surviving and thriving in this new era?

  • 5:25pm
    Closing Remarks from the Chair
  • 5:30pm
    End of conference

Why Attend?

  • Debate the role of super clusters and industrial strategy in creating a ‘big bang’ in life sciences
  • Discover how China’s novel approaches to R&D, data and digital health are creating innovate treatment and service models
  • Discuss what it takes for pharma to win in population health management and the business of prevention
  • Learn how innovative gene-based therapies are transforming the industry paradigm from treatment to cure and the pricing strategies to manage it.
  • Envision the future of diagnostics and personalised medicine
  • Hear from leading fund managers, corporate venturers, and other investors on where they are placing bets in pharma
  • Be part of the discussion on value and evidence and the challenge of managing the increasing volume and complexity of big data
fallback

Who Attends?

FT Live has a reputation for delivering very senior board level audiences to attend a wide range of world class thought-leadership events across the globe for nearly 40 years.

The FT Global Pharmaceutical and Biotechnology Conference will be attended by:

  • Pharmaceutical companies
  • Biotechnology companies
  • Diagnostic and medical devices
  • CROs
  • Healthcare providers and insurers
  • Government healthcare departments, HTA’s and drug regulators
  • Digital health companies
  • Genomics and personalised medicine experts
  • IT, big data and analytics providers
  • Health economists
  • Healthcare investment bankers, private equity and venture capitalists
  • Healthcare lawyers and management consultants
  • Patient representatives and NGOs
fallback

Fees

Ticket

Fee

Super Early Bird (ends 22 March)

£1699.00

Early Bird (ends 28 May)

£1799.00

Standard Summit Ticket

£1899.00

fallback

Sponsorship Opportunities

  • Gain access to 350 Senior Executives from the Pharmaceutical and Biotechnology industry, who will be attending the event;
  • Brand alignment with the FT and its unrivalled credibility;
  • Demonstrate thought leadership around the current critical issues affecting the Pharmaceutical and Biotechnology industry;
  • Benefit from sustained international visibility through our advertising and marketing campaigns

Joe Hames

Commercial Manager, Global Industries

T: +44 (0)207 873 4551

M: +44 (0)791 329 2038

E: joe.hames@ft.com

fallback

Presented by (1)

The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. In 2016 the FT passed a significant milestone in its digital transformation as digital and services revenues overtook print revenues for the first time. The FT has a combined paid print and digital circulation of more than 910,000 and makes 60% of revenues from its journalism.

Venue

Royal Lancaster
Lancaster Terrace
London W2 2TY

United Kingdom

Tel: +44 207 551 6000

fallback

Contact us

Alexsandra Silva
Media Partner and Press Enquiries
Financial Times
Angela Letinov
Speaking Opportunities
Financial Times
Joe Hames
Sponsorship Opportunities
Financial Times
Toby Barran
Delegate Booking and Registration Enquiries
Financial Times